This was especially pronounced for group 2 (loss of PMS2/MLH1 or MSH2/MSH6 without MSI), which included only 37% of CRC compared to 86.9% of CRC in classical MMR-D. This evidence concerns the gene MSH6 and colorectal carcinoma.